10 patents
Utility
Inhibiting Ataxia Telangiectasia and RAD3-RELATED Protein (Atr)
28 Dec 23
Novel compounds inhibiting ATR protein kinase include compounds of formula (I) disclosed herein, as well as liposome formulations comprising ATR protein kinase inhibitor compounds.
Daryl C. DRUMMOND, Bolin GENG, Dmitri B. KIRPOTIN, Suresh K. TIPPARAJU, Alexander KOSHKARYEV, Ozan ALKAN
Filed: 1 Sep 23
Utility
Remote Loading of Sparingly Water-Soluble Drugs Into Lipid Vesicles
7 Dec 23
The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases.
Mark E. HAYES, Charles O. NOBEL, Francis C. SZOKA
Filed: 17 Feb 23
Utility
Assays and Methods for Selecting a Treatment Regimen for a Subject with Leukemia
7 Sep 23
Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject.
Max GORDON, Paul TARDI, Jeffrey TYNER, Lawrence MAYER
Filed: 12 May 23
Utility
Liposomal Formulations of BCL Inhibitors
23 Feb 23
Provided herein are liposomes comprising B-cell lymphoma (Bcl) protein inhibitors, compositions comprising such liposomes, and methods using such formulations for treating hyperproliferative disorders.
Paul TARDI, Leon Wan, Shyam Madhusudan Garg, Jun Gao, Philippe Legros
Filed: 15 Jul 22
Utility
Low-intensity Treatment of Hematological Disorders
23 Dec 21
The invention relates to compositions and methods for treating patients with hematological proliferative disorders who are ineligible for treatment with standard intensive chemotherapy, using low intensity treatment with CPX-351, a liposomal composition of daunorubicin and cytarabine.
Ronald CHEUNG, Stefan FADERL, Qi WANG
Filed: 3 Jun 21
Utility
Inhibiting Ataxia Telangiectasia and RAD3-RELATED Protein (Atr)
30 Sep 21
Novel compounds inhibiting ATR protein kinase include compounds of formula (I) disclosed herein, as well as liposome formulations comprising ATR protein kinase inhibitor compounds.
Daryl C. DRUMMOND, Bolin GENG, Dmitri B. KIRPOTIN, Suresh K. TIPPARAJU, Alexander KOSHKARYEV, Ozan ALKAN
Filed: 7 May 21
Utility
Assays and Methods for Selecting a Treatment Regimen for a Subject with Leukemia
12 Aug 21
Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject.
Max GORDON, Paul TARDI, Jeffrey TYNER, Lawrence MAYER
Filed: 11 Feb 21
Utility
Method of Lyophilizing Liposomes
10 Jun 21
Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed.
Donna CABRAL-LILLY, Lawrence MAYER, Paul TARDI, David WATKINS, Yi ZENG
Filed: 13 Nov 20
Utility
Nanoparticle Delivery Systems
25 Feb 21
Nanoparticle compositions described herein comprise combinations of prodrugs of therapeutic agents that achieve enhanced therapeutic effects as compared to those observed when combinations of free forms of these therapeutic agents are administered.
Leon WAN, Winnie LUI, Paul TARDI, Lawrence MAYER
Filed: 4 Sep 20
Utility
Inhibiting Ataxia Telangiectasia and RAD3-RELATED Protein (Atr)
23 Dec 20
Novel compounds inhibiting ATR protein kinase include compounds of formula (I) disclosed herein, as well as liposome formulations comprising ATR protein kinase inhibitor compounds.
Daryl C. Drummond, Bolin Geng, Dmitri B. Kirpotin, Suresh K. Tipparaju, Alexander Koshkaryev, Ozan Alkan
Filed: 16 Jan 20
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first